Substance / Medication

Cyproheptadine

Overview

Active Ingredient
cyproheptadine
RxNorm CUI
3013

Indications

Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism adjunctive As therapy for anaphylactic reactionsto epinephrine and other standard measures after the acute manifestations have been controlled.

Labeler: Method Pharmaceuticals, LLCUpdated: 2025-10-21T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Newborn or Premature Infants: not This drug shouldbe used in newborn or premature infants. Nursing Mothers: Because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers. Other Conditions:

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

3 trials linked to this intervention

3
Total Trials
1
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Use of cyproheptadine to stimulate appetite and body weight gain: A systematic review.
Harrison Megan E, Norris Mark L, Robinson Amy et al. · Appetite · 2019
PMID: 30825493Meta-Analysis
Preventive effect of cyproheptadine on sleep and appetite disorders induced by methylphenidate: an exploratory randomised, double-blinded, placebo-controlled clinical trial.
Kadkhoda Mezerji Faezeh, Moharreri Fatemeh, Mohammadpour Amir Hooshang et al. · Int J Psychiatry Clin Pract · 2019
PMID: 30261781RCT
Cyproheptadine for the Prevention of Postoperative Delirium: A Pilot Study.
Mohammadi Mostafa, Ahmadi Motahareh, Khalili Hossein et al. · Ann Pharmacother · 2016
PMID: 26706862RCT
Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: a randomized clinical trial.
Dabaghzadeh Fatemeh, Ghaeli Padideh, Khalili Hossein et al. · AIDS Patient Care STDS · 2013
PMID: 23442031RCT
Short-term cyproheptadine therapy in underweight children: effects on growth and serum insulin-like growth factor-I.
Mahachoklertwattana Pat, Wanasuwankul Santhira, Poomthavorn Preamrudee et al. · J Pediatr Endocrinol Metab · 2009
PMID: 19618661RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Cyproheptadine (substance)
SNOMED CT
372683000
UMLS CUI
C0010620
RxNorm CUI
3013
Labeler
Method Pharmaceuticals, LLC

Clinical Data

This intervention maps to 8 entities in the Healos knowledge graph.

8
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
3
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.